Vladimir Lj Lazarevic1,2, Aldana Rosso3,4, Gunnar Juliusson1,2, Petar Antunovic5, Åsa Rangert Derolf6, Stefan Deneberg6, Lars Möllgård7, Bertil Uggla8, Lovisa Wennström7, Anders Wahlin9, Martin Höglund10, Sören Lehmann10, Bertil Johansson11,12. 1. Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. 2. Stem Cell Center, Lund University, Lund, Sweden. 3. Epidemiology and Registry Center in South Sweden, Skåne University Hospital, Lund, Sweden. 4. Medical Radiology, Department of Translational Medicine, Lund University, Lund, Sweden. 5. Department of Hematology, Linköping University Hospital, Linköping, Sweden. 6. Department of Medicine, Division of Hematology, Karolinska University Hospital, Stockholm, Sweden. 7. Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden. 8. Department of Medicine, School of Health and Medical Sciences, Örebro University Hospital, Örebro, Sweden. 9. Department of Radiation Sciences, Umeå University, Umeå, Sweden. 10. Department of Hematology, Academic Hospital, Uppsala, Sweden. 11. Department of Clinical Genetics, University and Regional Laboratories Region Skåne, Lund, Sweden. 12. Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Abstract
OBJECTIVES AND METHODS: To ascertain the incidence/clinical implications of isolated autosomal trisomies in adult acute myeloid leukemia (AML), all such cases were retrieved from the Swedish AML Registry. RESULTS: Of the 3179 cytogenetically informative AMLs diagnosed January 1997-May 2015, 246 (7.7%) had isolated trisomies. The frequency increased by age (2.4% at age 18-60 years vs. 23% at >60 years; P<.0001); the median age was 69 years. The five most common were +8 (4.0%), +13 (0.9%), +11 (0.8%), +21 (0.7%), and +4 (0.5%). Age and gender, types of AML and treatment, and complete remission and early death rates did not differ between the single trisomy and the intermediate risk (IR) groups or among cases with isolated gains of chromosomes 4, 8, 11, 13, or 21. The overall survival (OS) was similar in the single trisomy (median 1.6 years) and IR groups (1.7 years; P=.251). The OS differed among the most frequent isolated trisomies; the median OS was 2.5 years for +4, 1.9 years for +21, 1.5 years for +8, 1.1 years for +11, and 0.8 years for +13 (P=.013). CONCLUSION: AML with single trisomies, with the exception of +13, should be grouped as IR.
OBJECTIVES AND METHODS: To ascertain the incidence/clinical implications of isolated autosomal trisomies in adult acute myeloid leukemia (AML), all such cases were retrieved from the Swedish AML Registry. RESULTS: Of the 3179 cytogenetically informative AMLs diagnosed January 1997-May 2015, 246 (7.7%) had isolated trisomies. The frequency increased by age (2.4% at age 18-60 years vs. 23% at >60 years; P<.0001); the median age was 69 years. The five most common were +8 (4.0%), +13 (0.9%), +11 (0.8%), +21 (0.7%), and +4 (0.5%). Age and gender, types of AML and treatment, and complete remission and early death rates did not differ between the single trisomy and the intermediate risk (IR) groups or among cases with isolated gains of chromosomes 4, 8, 11, 13, or 21. The overall survival (OS) was similar in the single trisomy (median 1.6 years) and IR groups (1.7 years; P=.251). The OS differed among the most frequent isolated trisomies; the median OS was 2.5 years for +4, 1.9 years for +21, 1.5 years for +8, 1.1 years for +11, and 0.8 years for +13 (P=.013). CONCLUSION:AML with single trisomies, with the exception of +13, should be grouped as IR.
Authors: Bhavana Bhatnagar; Ann-Kathrin Eisfeld; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Dimitrios Papaioannou; Christopher J Walker; Shelley Orwick; James S Blachly; Jonathan E Kolitz; Bayard L Powell; Andrew J Carroll; Richard M Stone; John C Byrd; Clara D Bloomfield Journal: Leukemia Date: 2019-08-28 Impact factor: 11.528
Authors: Jan Philipp Bewersdorf; Rory M Shallis; Autumn Diadamo; Lohith Gowda; Nikolai A Podoltsev; Alexa Siddon; Amer M Zeidan Journal: Leuk Lymphoma Date: 2020-04-26